Drug updated on 12/11/2024
| Dosage Form | Tablet (oral; 200 mg) |
| Drug Class | Methyltransferase inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection
- Indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies
- Indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options.
Latest News
Summary
- This summary is based on the review of two systematic review(s)/meta-analysis(es). [1-2]
- Effectiveness in Enhancer of Zeste Homolog 2 (EZH2) Wild-Type Patients: Mosunetuzumab demonstrated superior effectiveness compared to tazemetostat in EZH2 wild-type patients, showing better outcomes in complete response (CR), objective response rate (ORR), and progression-free survival (PFS).
- Comparison with phosphatidylinositol 3-kinase (PI3K) Inhibitors: Tazemetostat showed no significant difference in ORR when compared to PI3K inhibitors (idelalisib, duvelisib, copanlisib, umbralisib), indicating comparable efficacy across these treatment options.
- Tazemetostat Safety Profile: Tazemetostat demonstrated a lower risk of grade ≥ 3 treatment-emergent adverse events (TEAEs), serious TEAEs, and TEAEs leading to dose reduction, drug discontinuation, or interruption compared to PI3K inhibitors (idelalisib, duvelisib, copanlisib, umbralisib).
- Discontinuations Due to Adverse Events: Fewer discontinuations due to adverse events were reported for mosunetuzumab compared to tazemetostat and PI3K inhibitors.
- Specific Population Types and Subgroups: Mosunetuzumab demonstrated better effectiveness in EZH2 wild-type patients compared to tazemetostat, as shown by superior complete response (CR), objective response rate (ORR), and progression-free survival (PFS). Tazemetostat included patients with grade 3b or transformed follicular lymphoma (FL), though specific outcomes for this subgroup were not detailed. Only the tazemetostat trial recorded EZH2 mutation status, but its relevance to outcomes was not explicitly outlined.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Tazverik (tazemetostat) Prescribing Information. | 2024 | Epizyme Inc., Cambridge, MA |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Translational Aspects of Epithelioid Sarcoma – Current Consensus | 2024 | Clinical Cancer Research |